Physician
Oncology
Dr. Avi Markowitz, MD
|
|
Give Review
Dr. Avi Markowitz is an expert in the field of Oncology. He studied medicine at University of California San Francisco School of Medicine. University of California San Francisco School of Medicine is a top medical university. University of California San Francisco School of Medicine is ranked 3 in research and 3 in primary care medicine He over the years received 1 awards: "CMS Meaningful Use Stage 1 Certification". Doctor Avi Markowitz, MD is a published doctor. He has 21 papers published. The most current publication "Phase II trial of recombinant IFN-alpha2a with etoposide/cisplatin induction and interferon/megestrol acetate maintenance in extensive small cell lung cancer." He accepts Medicare payments and is registered with Medicare.gov.
Publications
- Alternative therapy for epstein-barr virus related hemophagocytic lymphohistiocytosis.
- Intraperitoneal catheters: percutaneous placement with fluoroscopic guidance.
- Interleukin-2 alone and in combination with other cytokines in melanoma: the investigational approach at the University of Texas M.D. Anderson Cancer Center.
- Suppression of chronic myelogenous Leukemia colony growth by interleukin-4.
- Surgery following response to interferon-alpha-based therapy for residual renal Cell carcinoma.
- Effect of recombinant human interleukin 4 on human monocyte activity.
- Immunological properties of melanoma tumor-infiltrating lymphocytes before and after IL-2-based biotherapies.
- Study of tumor-infiltrating lymphocytes for adoptive therapy of renal Cell carcinoma (RCC) and metastatic melanoma: sequential proliferation of cytotoxic natural kille...
- A phase II study of interleukin-2 and lymphokine-activated killer Cells in patients with metastatic malignant melanoma.
- Novel tumor necrosis factor toxic effects. Pulmonary hemorrhage and severe hepatic dysfunction.
- Phase II trial of recombinant IFN-alpha2a with etoposide/cisplatin induction and interferon/megestrol acetate maintenance in extensive small cell lung Cancer.
- Phase II study of etoposide and alpha-interferon in patients with advanced measurable coloRectal carcinoma.
- Phase I and plasma pharmacokinetic study of infusional fluorouracil combined with recombinant interferon alfa-2b in patients with advanced Cancer.
- Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic coloRectal carcinoma.
- Irregular echogenic foci representing Coagulation necrosis: a useful but perhaps under-recognized EUS echo feature of malignant lymph node invasion.
- Sweet syndrome associated with granulocyte colony-stimulating factor.
- Knowledge of indications and utilization of EUS: a survey of oncologists in the United States.
- Temporal trends and predictors of perioperative chemotherapy use in elderly patients with resected nonsmall cell lung Cancer.
- Mirtazapine for depression and comorbidities in older patients with Cancer.
- Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial Cancer.
Schools
University of California At San Francisco
Ucsd Hosps
Ucsf Hosps
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Amerigroup (Wellpoint)
- Blue Card PPO
- Blue Advantage HMO
- Blue Choice
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- LocalPlus
- Open Access Plus
- Commercial Insurance Company
- Federal Employee Program (FEP)
- Health Alliance
- Choice Care PPO
- Preferred PPO
- Medicaid
- Medicare MCR
- Molina
- MultiPlan PPO
- PHCS Network PPO
- Tricare
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
University of California San Diego -
University of California San Francisco School of Medicine
Drug Facts
| NPI NUMBER | 1336155662 | |
| NPPES Provider LastName | MARKOWITZ | |
| NPPES Provider FirstName | AVI | |
| NPPES Provider ZIPCode | 775551022 | |
| NPPES Provider State | TX | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 163.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 24.0 | |
| Percent Opioid Claims | 14.72 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1336155662 |
| Last Name Of The Provider | MARKOWITZ |
| First Name Of The Provider | AVI |
| View All |
Similar Doctors
|
|
Dr. Haris Baig, DO |
|
|
Dr. Techksell M. McKnight, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bagi R. Janarthanan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Maria E. Montoya, MD |
|
|
Dr. Sri J. Obulareddy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Issam A. Alawin, MB BS
This Doctor is OpenDoctor Recommended.
|